Drugs / Recombinant Human TPO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05333744 | Jun 2021 → Jun 2022 | thrombocytopenia due to immune destruction | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human TPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05333744 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human TPO” NCT05333744 ↗ |
| Route | Intramuscular | “rhTPO im, 300U/kg per day for 2 weeks” NCT05333744 ↗ |